Worth reading
22Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
12
New active ingredients (first patient dosed in a Phase I trial)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Medium-Term Management Plan Presentation3 items taken from the company’s own explanation
What the company explained in this material
New initiatives
- Transform the entire R&D organization into a global, end-to-end structure
- Invest in AI-enabled protein design, AI-driven gene therapy and Human-in-the-Loop platforms
- Use Evinova's AI-native Study Designer platform
- Automate cell therapy manufacturing through the Mahol-A-Ba robotics platform
- Insourcing clinical operations
- Strategic partnership with Vir Biotechnology for the development and commercialization of VIR-5500 (before completion of the transaction)
Key KPIsA metric the company considers important as a management benchmark.
- Number of patients treated with Astellas products174 million patients
- Number of countries where products are availableMore than 100 countries
- Reduction in the time from IND acceptance to activation of the first clinical trial site69%Year on year against the same period last yearFY24/FY25 vs. FY23
- Reduction in the time from IND acceptance to first patient dosing67%Year on year against the same period last yearFY24/FY25 vs. FY23
- Median time from receipt of topline results to filing115 days
- Reduction in the timeline to filing14%Year on year against the same period last yearFY25 vs. FY23
- Number of approvals obtained for priority strategic products in key regions8 items
Medium-term management plan targets
- TargetAdvance 10 new active ingredients to the Phase III stageTarget fiscal yearThrough 2034
- TargetRaise R&D productivity to a top-tier industry levelTarget fiscal year2030-2034
| Item | Details |
|---|---|
| Document type | Medium-Term Management Plan Presentation |
| Key KPIs | Indicator name Number of patients treated with Astellas products / Value 174 million patients / Year on year against the same period last year Not disclosed, Indicator name Number of countries where products are available / Value More than 100 countries / Year on year against the same period last year Not disclosed, Indicator name Reduction in the time from IND acceptance to activation of the first clinical trial site / Value 69% / Year on year against the same period last year FY24/FY25 vs. FY23, Indicator name Reduction in the time from IND acceptance to first patient dosing / Value 67% / Year on year against the same period last year FY24/FY25 vs. FY23, Indicator name Median time from receipt of topline results to filing / Value 115 days / Year on year against the same period last year Not disclosed, Indicator name Reduction in the timeline to filing / Value 14% / Year on year against the same period last year FY25 vs. FY23, Indicator name Number of approvals obtained for priority strategic products in key regions / Value 8 items / Year on year against the same period last year Not disclosed |
| Medium-term management plan targets | Target Advance 10 new active ingredients to the Phase III stage / Target fiscal year Through 2034, Target Raise R&D productivity to a top-tier industry level / Target fiscal year 2030-2034 |
| New initiatives | Transform the entire R&D organization into a global, end-to-end structure, Invest in AI-enabled protein design, AI-driven gene therapy and Human-in-the-Loop platforms, Use Evinova's AI-native Study Designer platform, Automate cell therapy manufacturing through the Mahol-A-Ba robotics platform, Insourcing clinical operations, Strategic partnership with Vir Biotechnology for the development and commercialization of VIR-5500 (before completion of the transaction) |
Items this document does not state (27)
Fiscal Period CoveredNet SalesOperating profitOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To accelerate the delivery of value to patients, improve R&D productivity and efficiency, and shift to a long-term growth trajectory after the expiration of XTANDI's exclusivity period. The company said it would concentrate on higher-value programs, strengthen clinical trial execution capabilities and invest in capabilities such as AI.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.